In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 99, Issue 1, 2005, Pages 62-70

  Thapar, Mita M ^a   Gil, Jose P ^a   Björkman, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atovaquone; Dormant state; Malaria; Malarone ; Plasmodium falciparum; Proguanil

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CYCLOGUANIL; CYTOCHROME B; PROGUANIL;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FOLLOW UP; IN VITRO STUDY; INCUBATION TIME; MALARIA FALCIPARUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE CULTIVATION; PARASITEMIA; PLASMODIUM FALCIPARUM; POINT MUTATION; SCHIZONT; TROPHOZOITE;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHLOROGUANIDE; CULTURE MEDIA; CYTOCHROME B GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; NAPHTHOQUINONES; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; RECURRENCE; TRIAZINES;

PLASMODIUM FALCIPARUM;

EID: 8744262888     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2004.01.016     Document Type: Article

References (43)

1. M.H. Alin A. Bjorkman Concentration and time dependency of artemisinin efficacy against Plasmodium falciparum in vitro Am. J. Trop. Med. Hyg. 50 1994 771-776
2. Y. Bergqvist L. Funding A. Kaneko B. Krysen T. Leek Improved method for the simultaneous determination of proguanil and its metabolites by high-performance liquid chromatography and solid-phase extraction of 100-microl capillary blood samples dried on sampling paper J. Chromatogr. B. Biomed. Sci. Appl. 719 1998 141-149
3. C.J. Canfield M. Pudney W.E. Gutteridge Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro Exp. Parasitol. 80 1995 373-381
4. M.D. Edstein S. Looareesuwan C. Viravan D.E. Kyle Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone Southeast Asian J. Trop. Med. Public Health 27 1996 216-220
5. B. Eriksson M. Lebbad A. Bjorkman In vitro activity of proguanil, chlorproguanil and their main metabolites against Plasmodium falciparum Trans. R. Soc. Trop. Med. Hyg. 83 1989 488
6. A. Farnert J. Lindberg P. Gil G. Swedberg Y. Berqvist M.M. Thapar N. Lindegardh S. Berezcky A. Bjorkman Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: Case reports BMJ 326 2003 628-629
7. D.A. Fidock T. Nomura T.E. Wellems Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase Mol. Pharmacol. 54 1998 1140-1147
8. Q.L. Fivelman G.A. Butcher I.S. Adagu D.C. Warhurst G. Pasvol Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria Malaria Journal 1 2002 1
9. M. Fry M. Pudney Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80) Biochem. Pharmacol. 43 1992 1545-1553
10. J.P. Gil F. Nogueira J. Stromberg-Norklit J. Lindberg M. Carrolo C. Casimiro D. Lopes A.P. Arez P.V. Cravo V.E. Rosario Detection of atovaquone and Malarone resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb) Mol. Cell. Probes. 17 2003 85-89
11. C. Gillotin J.P. Mamet L. Veronese Lack of a pharmacokinetic interaction between atovaquone and proguanil Eur. J. Clin. Pharmacol. 55 1999 311-315
12. A.M. Gunasekera S. Patankar J. Schug G. Eisen D.F. Wirth Drug-induced alterations in gene expression of the asexual blood forms of Plasmodium falciparum Mol. Microbiol. 50 2003 1229-1239
13. B. Hogh P.D. Clarke D. Camus H.D. Nothdurft D. Overbosch M. Gunther I. Joubert K.C. Kain D. Shaw N.S. Roskell J.D. Chulay Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double-blind study. Malarone International Study Team Lancet 356 2000 1888-1894
14. M.B. Hoshen K. Na-Bangchang W.D. Stein H. Ginsburg Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: Postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens Parasitology 121 2000 237-246
15. M.B. Joshi D.T. Lin P.H. Chiang N.D. Goldman H. Fujioka M. Aikawa C. Syin Molecular cloning and nuclear localization of a histone deacetylase homologue in Plasmodium falciparum Mol. Biochem. Parasitol. 99 1999 11-19
16. A. Kaneko Y. Bergqvist G. Taleo T. Kobayakawa T. Ishizaki A. Bjorkman Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations Pharmacogenetics 9 1999 317-326
17. B.J. Kilbey I. Fraser S. McAleese M. Goman R.G. Ridley Molecular characterisation and stage-specific expression of proliferating cell nuclear antigen (PCNA) from the malarial parasite, Plasmodium falciparum Nucleic Acids Res. 21 1993 239-243
18. M. Korsinczky N. Chen B. Kotecka A. Saul K. Rieckmann Q. Cheng Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site Antimicrob. Agents Chemotherapy 44 2000 2100-2108
19. N. Lindegardh Y. Bergqvist Automated solid-phase extraction method for the determination of atovaquone in plasma and whole blood by rapid high-performance liquid chromatography J. Chromatogr. B. Biomed. Sci. Appl. 744 2000 9-17
20. J.T. Litchfield F. Wilcoxon A simplified method of evaluating dose-effect experiments J. Pharmacol. Ther. 108 1953 18-25
21. S. Looareesuwan C. Viravan H.K. Webster D.E. Kyle D.B. Hutchinson C.J. Canfield Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand Am. J. Trop. Med. Hyg. 54 1996 62-66
22. S. Looareesuwan P. Wilairatana K. Chalermarut Y. Rattanapong C.J. Canfield D.B. Hutchinson Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand Am. J. Trop. Med. Hyg. 60 1999 526-532
23. A.D. Murphy N. Lang-Unnasch Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum Antimicrob. Agents. Chemotherapy 43 1999 651-654
24. S. Nakazawa H. Kanbara M. Aikawa Plasmodium falciparum: Recrudescence of parasites in culture Exp. Parasitol. 81 1995 556-563
25. S. Nakazawa T. Maoka H. Uemura Y. Ito H. Kanbara Malaria parasites giving rise to recrudescence in vitro Antimicrob. Agents. Chemotherapy 46 2002 958-965
26. D. Overbosch H. Schilthuis U. Bienzle R.H. Behrens K.C. Kain P.D. Clarke S. Toovey J. Knobloch H.D. Nothdurft D. Shaw N.S. Roskell J.D. Chulay Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: Results from a randomized, double-blind study Clin. Infect. Dis. 33 2001 1015-1021
27. S. Patterson C. Whittle C. Robert D. Chakrabarti Molecular characterization and expression of an alternate proliferating cell nuclear antigen homologue, PfPCNA2, in Plasmodium falciparum Biochem. Biophys. Res. Commun. 298 2002 371-376
28. P.D. Radloff J. Philipps D. Hutchinson P.G. Kremsner Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria Trans. R. Soc. Trop. Med. Hyg. 90 1996 682
29. W. Richards B. Maples Studies on Plasmodium falciparum in continuous cultivation. The effect of chloroquine and pyrimethamine on parasite growth and viability Ann. Trop. Med. Parasitol. 73 1979 99-108
30. I.K. Srivastava J.M. Morrisey E. Darrouzet F. Daldal A.B. Vaidya Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites Mol. Microbiol. 33 1999 704-711
31. F. Sucharit S. Tiewcharoen T. Chintana V. Suphadtanaphongs S. Sucharit In vitro studies on the sensitivities of Plasmodium falciparum in Thailand to pyrimethamine and proguanil Ann. Trop. Med. Parasitol. 79 1985 375-377
32. T.Y. Sukwa M. Mulenga N. Chisdaka N.S. Roskell T.R. Scott A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia Am. J. Trop. Med. Hyg. 60 1999 521-525
33. M. Thapar S. Gupta C. Spindler W. Wernsdorfer A. Björkman In vitro pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum Trans. R. Soc. Trop. Med. Hyg. 97 2003 331-337
34. M.M. Thapar M. Ashton N. Lindegardh Y. Bergqvist S. Nivelius I. Johansson A. Bjorkman Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis Eur. J. Clin. Pharmacol. 58 2002 19-27
35. W. Trager J.B. Jensen Human malaria parasites in continuous culture Science 193 1976 673-675
36. A.B. Vaidya M.W. Mather Atovaquone resistance in malaria parasites Drug Resist. Updat. 3 2000 283-287
37. K.L. Waller R.A. Muhle L.M. Ursos P. Horrocks D. Verdier-Pinard A.B. Sidhu H. Fujioka P.D. Roepe D.A. Fidock Chloroquine resistance modulated in vitro by expression levels of the Plasmodium falciparum chloroquine resistance transporter J. Biol. Chem. 278 2003 33593-33601
38. N.C. Waters J.A. Geyer Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development Expert Opin. Ther. Targets 7 2003 7-17
39. W.M. Watkins E.K. Mberu C.G. Nevill S.A. Ward A.M. Breckenridge D.K. Koech Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults Trans. R. Soc. Trop. Med. Hyg. 84 1990 492-495
40. G. Watt Atovaquone-proguanil for falciparum malaria in the Philippines J. Infect. Dis. 181 2000 405
41. W.H. Wernsdorfer Epidemiology of drug resistance in malaria Acta Trop. 56 1994 143-156
42. Z.G. Ye Z.L. Li G.Q. Li X.Q. Fu H.P. Liu M.X. Gao Effects of Qinghaosu and chloroquine on the ultrastructure of the erythrocytic stage of P. falciparum in continuous cultivation in vitro J. Trad. Chin. Med. 3 1983 95-102
43. Q. Zhou M.A. McCracken J.S. Strobl Control of mammary tumor cell growth in vitro by novel cell differentiation and apoptosis agents Breast Cancer Res. Treat. 75 2002 107-117